Regeneron Antibodies Prevent Symptomatic COVID-19 In Interim Phase III Data

Efficacy Data On Casirivimab/Imdevimab In Mutant Strains Forthcoming

 
• By Alaric DeArment
  
Antibodies immunoglobulins attacking coronavirus covid-19 influenza virus cell, 3D immune system medical illustration background. Corona virus 2019-ncov sars cell, igm. Coronavirus sars-cov-2 disease
Interim data from Regeneron's Phase III study show its antibody cocktail is effective at preventing symptomatic COVID-19. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

More from Scrip